Gastroenterology
Efficacy comparison of high-genetic barrier nucleos(t)ide analogues in treatment-naïve chronic hepatitis B patients: a network meta-analysis
Jaejun Lee, Ahlim Lee, Pil Soo Sung, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Hyun Yang
Korean J Intern Med. 2024;39(4):577-589. Published online June 13, 2024
Background/Aims: Four high-genetic barrier nucleos(t)ide analogues (NAs) for chronic hepatitis B (CHB), namely entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and besifovir dipivoxil maleate (BSV), have been established. The aim of this study is to investigate the ..
|
|
Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma
Byung Soo Kwan, Jeong Han Kim, Seong Jun Park, Won Hyeok Choe, So Young Kwon, Byung-Chul Yoo
Korean J Intern Med. 2021;36(2):292-304. Published online April 3, 2020
Background/Aims: Chronic hepatitis C (CHC) treatment has dramatically improved since direct-acting antiviral (DAA) therapy was introduced. However, the use of DAA therapy in CHC patients with hepatocellular carcinoma (HCC) remains controversial. We investigated the DAA treatment response in CHC pati..
|
|
Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study
Jae Yoon Jeong, Dae Won Jun, Sol Ji Park, Joo Hyun Sohn, Sang Gyune Kim, Se Whan Lee, Soung Won Jeong, Moon Young Kim, Won Kim, Jae-Jun Shim, Hyoung Su Kim, Ki Tae Suk, Sang Bong Ahn
Korean J Intern Med. 2020;35(5):1074-1083. Published online November 12, 2019
Background/Aims: We aimed to assess the role of vitamin D supplementation in the response to pegylated interferon-α (PEG-IFN-α) plus ribavirin (RBV) treatment in patients with chronic hepatitis C (CHC).
Methods: Our study was a multi-center, randomized controlled trial in 11 hospitals. CHC patient..
|
|
|